Spyre Therapeutics
SYRE
SYRE
197 hedge funds and large institutions have $4.16B invested in Spyre Therapeutics in 2026 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 66 increasing their positions, 49 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
35% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 49
29% more funds holding
Funds holding: 153 → 197 (+44)
0.87% more ownership
Funds ownership: 104.36% → 105.23% (+0.87%)
Holders
197
Holding in Top 10
10
Calls
$16.4M
Puts
$1.55M
Top Buyers
| 1 | +$34.5M | |
| 2 | +$33.1M | |
| 3 | +$30.5M | |
| 4 |
PA
Perceptive Advisors
New York
|
+$26.9M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$18.5M |
Top Sellers
| 1 | -$65.8M | |
| 2 | -$26.5M | |
| 3 | -$23.3M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.7M |
| 5 |
CC
Commodore Capital
New York
|
-$17.9M |
